UNSPSC 51392412: Dopamine hydrochloride

This classification denotes a dopamine agent with the molecular formula C8H11NO2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7L3E358N9L, chemically known as 3,4-dihydroxyphenylethylamine but more generally known as dopamine hydrochloride, which bears US NIH Compound Identifier 681. European Medicines Agency schedules Dopamine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01818MIG.

Most nations, for tariff and trade purposes, schedule dopamine hydrochloride under HS 29222900 and SITC 51462. As of Q4 2014, DOPAMINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Dopamine hydrochloride bears US NLM identifiers UMLS ID C0282151 and NCI Concept Code C455. SMILES: C1CC(C(CC1CCN)O)O.CL.

UNSPSC 51392412 Dopamine hydrochloride is a Commodity code representing pharmaceutical active ingredients and finished pharmaceutical products procured by state and local health agencies. Recent solicitations under this code reflect state and local governments acquiring naloxone, drug deactivation systems, and prescription fulfillment services to support community health initiatives, addiction prevention, and pharmacy benefit programs. Issuing bodies include county health departments and state health and human services commissions, particularly those managing public health emergency response, opioid mitigation, and employee pharmacy benefits.

Seminole County, Florida released IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023, for quarterly delivery to the Seminole County Community Health Building. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, requesting vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program to establish direct relationships between the state pharmacy benefit program and pharmaceutical manufacturers, signaling exploratory procurement that will likely lead to a formal RFP. Geographic activity is concentrated in the Southeast (Florida) and South (Texas), though the breadth of the state HHS inquiry suggests broader potential demand across state employee and retiree pharmacy benefit programs nationally.